Philadelphia freedom as Boyds lands in the US
Boyds, the Cambridge pharmaceutical and biotech product development consultancy, has opened a US office in the Philadelphia area to support continued growth opportunities.
The company has also appointed Katy Rudnick as VP and head of US Regulatory Affairs to head up the US business.
Since Boyds was established in 2005 it has worked with US companies seeking to develop and gain approval for medicines in Europe and further afield.
Boyds’ global reputation for its work in advanced therapies has led to a steady increase in the number of companies approaching it for services and more than 60 per cent of the company’s client base is now anchored in the US.
The new office in Pennsylvania is regarded as an ideal location for many of Boyds’ East Coast clients and provides a link between different time zones from Europe to the West Coast.
Katy Rudnick brings 20 years of regulatory and quality experience in the US, having worked across all therapeutic areas and dosage forms.
Prior to joining Boyds, Katy was Director of Regulatory Affairs at Lupin Pharmaceuticals where she was responsible for a product portfolio of around 400 products at various stages. She has also held regulatory roles at Lannett Company, Teva Pharmaceuticals and Mars Fishcare North America.
President and founder of Boyds, Professor Alan Boyd, said: “The US is the largest biotech market globally and we have a strong and growing client base in the US.
“Opening the office in Pennsylvania is the natural next step for Boyds and having a presence on the ground will ensure we can work closely with US clients looking to develop and take their products forward for approval with regulators in the US, as well as the UK and Europe, via our UK and Dublin offices.”